Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2011

Open Access 01-12-2011 | Research

Peroxisome proliferator-activated receptor α (PPARα) mRNA expression in human hepatocellular carcinoma tissue and non-cancerous liver tissue

Authors: Tsuyoshi Kurokawa, Yoshiharu Shimomura, Gustavo Bajotto, Katsuhiro Kotake, Takashi Arikawa, Nobuhiro Ito, Akira Yasuda, Hiroshi Nagata, Toshiaki Nonami, Kazuo Masuko

Published in: World Journal of Surgical Oncology | Issue 1/2011

Login to get access

Abstract

Background

Peroxisome proliferator-activated receptor α (PPARα) regulates lipid metabolism in the liver. It is unclear, however, how this receptor changes in liver cancer tissue. On the other hand, mouse carcinogenicity studies showed that PPARα is necessary for the development of liver cancer induced by peroxisome proliferators, and the relationship between PPARα and the development of liver cancer have been the focus of considerable attention. There have been no reports, however, demonstrating that PPARα is involved in the development of human liver cancer.

Methods

The subjects were 10 patients who underwent hepatectomy for hepatocellular carcinoma. We assessed the expression of PPARα mRNA in human hepatocellular carcinoma tissue and non-cancerous tissue, as well as the expression of target genes of PPARα, carnitine palmitoyltransferase 1A and cyclin D1 mRNAs. We also evaluated glyceraldehyde 3-phosphate dehydrogenase, a key enzyme in the glycolytic system.

Results

The amounts of PPARα, carnitine palmitoyltransferase 1A and glyceraldehyde 3-phosphate dehydrogenase mRNA in cancerous sections were significantly increased compared to those in non-cancerous sections. The level of cyclin D1 mRNA tends to be higher in cancerous than non-cancerous sections. Although there was a significant correlation between the levels of PPARα mRNA and cyclin D1 mRNA in both sections, however the correlation was higher in cancerous sections.

Conclusion

The present investigation indicated increased expression of PPARα mRNA and mRNAs for PPARα target genes in human hepatocellular carcinoma. These results might be associated with its carcinogenesis and characteristic features of energy production.
Appendix
Available only for authorised users
Literature
1.
go back to reference Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ: Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J Biol Chem. 1998, 273: 5678-5684. 10.1074/jbc.273.10.5678.CrossRefPubMed Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ: Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J Biol Chem. 1998, 273: 5678-5684. 10.1074/jbc.273.10.5678.CrossRefPubMed
2.
go back to reference Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptorα activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000, 275: 16638-16642. 10.1074/jbc.275.22.16638.CrossRefPubMed Guerre-Millo M, Gervois P, Raspé E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptorα activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000, 275: 16638-16642. 10.1074/jbc.275.22.16638.CrossRefPubMed
3.
go back to reference Lee CH, Olson P, Evance RM: Minireview: lipid metabolism, metabolic diseases and peroxisome proliferator-activated receptors. Endocrinology. 2003, 144: 2201-2207. 10.1210/en.2003-0288.CrossRefPubMed Lee CH, Olson P, Evance RM: Minireview: lipid metabolism, metabolic diseases and peroxisome proliferator-activated receptors. Endocrinology. 2003, 144: 2201-2207. 10.1210/en.2003-0288.CrossRefPubMed
4.
go back to reference Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-muscles is inhibited by PPARα but not PPARγ activators. Nature. 1998, 393: 790-793. 10.1038/31701.CrossRefPubMed Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-muscles is inhibited by PPARα but not PPARγ activators. Nature. 1998, 393: 790-793. 10.1038/31701.CrossRefPubMed
5.
go back to reference Jiang C, Ting At, Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998, 391: 82-86. 10.1038/34184.CrossRefPubMed Jiang C, Ting At, Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998, 391: 82-86. 10.1038/34184.CrossRefPubMed
6.
go back to reference Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner-Crisp PA: PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol. 2003, 33: 655-780. 10.1080/713608372.CrossRefPubMed Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner-Crisp PA: PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol. 2003, 33: 655-780. 10.1080/713608372.CrossRefPubMed
7.
go back to reference Peters JM, Aoyama T, Cattley RC, Usuda N, Hashimoto T, Gonzalez FJ: Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver. Carcinogenesis. 1998, 19: 1989-1994. 10.1093/carcin/19.11.1989.CrossRefPubMed Peters JM, Aoyama T, Cattley RC, Usuda N, Hashimoto T, Gonzalez FJ: Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver. Carcinogenesis. 1998, 19: 1989-1994. 10.1093/carcin/19.11.1989.CrossRefPubMed
8.
go back to reference Reddy JK, Hashimoto T: Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr. 2001, 21: 193-230. 10.1146/annurev.nutr.21.1.193.CrossRefPubMed Reddy JK, Hashimoto T: Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr. 2001, 21: 193-230. 10.1146/annurev.nutr.21.1.193.CrossRefPubMed
9.
go back to reference Reddy JK: Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. Cancer Res. 1976, 36: 1211-1217.PubMed Reddy JK: Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. Cancer Res. 1976, 36: 1211-1217.PubMed
10.
go back to reference Chomczynski P: A reagent for single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques. 1993, 15: 532-536.PubMed Chomczynski P: A reagent for single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques. 1993, 15: 532-536.PubMed
11.
go back to reference Weber AW: Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005, 46: 983-995.PubMed Weber AW: Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005, 46: 983-995.PubMed
12.
go back to reference Kostakoglu L, Goldsmith SJ: PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med. 2004, 45: 56-68.PubMed Kostakoglu L, Goldsmith SJ: PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med. 2004, 45: 56-68.PubMed
13.
go back to reference Kostakoglu L, Goldsmith SJ: 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med. 2003, 44: 224-239.PubMed Kostakoglu L, Goldsmith SJ: 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med. 2003, 44: 224-239.PubMed
14.
go back to reference Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK, Pinson CW: Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998, 133: 510-516. 10.1001/archsurg.133.5.510.CrossRefPubMed Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK, Pinson CW: Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998, 133: 510-516. 10.1001/archsurg.133.5.510.CrossRefPubMed
15.
go back to reference Takahashi N, Kawada T, Goto T, Yamamoto T, Taimatsu A, Matsui N, Kimura K, Saito M, Hosokawa M, Miyashita K, Fushiki T: Dual action of isoprenols from herbal medicines on both PPAR-gamma and PPAR-alpha in 3T3-L1 adipocytes and HepG2 hepatocytes. FEBS Lett. 2002, 514: 316-322. Takahashi N, Kawada T, Goto T, Yamamoto T, Taimatsu A, Matsui N, Kimura K, Saito M, Hosokawa M, Miyashita K, Fushiki T: Dual action of isoprenols from herbal medicines on both PPAR-gamma and PPAR-alpha in 3T3-L1 adipocytes and HepG2 hepatocytes. FEBS Lett. 2002, 514: 316-322.
16.
go back to reference Takahashi N, Kawada T, Goto T, Kim CS, Taimatsu A, Egawa K, Yamamoto T, Jisaka M, Nishimura K, Yokota K, Yu R, Fushiki T: Abietic acid activates PPAR-gamma in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism. FEBS Lett. 2003, 550: 190-194. 10.1016/S0014-5793(03)00859-7.CrossRefPubMed Takahashi N, Kawada T, Goto T, Kim CS, Taimatsu A, Egawa K, Yamamoto T, Jisaka M, Nishimura K, Yokota K, Yu R, Fushiki T: Abietic acid activates PPAR-gamma in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism. FEBS Lett. 2003, 550: 190-194. 10.1016/S0014-5793(03)00859-7.CrossRefPubMed
17.
go back to reference Nakashima H, Nonami T, Shimomura Y, Naruse T: Quantification of mRNAs for pyruvate dehydrogenase kinases in human livers. J Aichi Med Univ Assoc. 2001, 29: 75-81. Nakashima H, Nonami T, Shimomura Y, Naruse T: Quantification of mRNAs for pyruvate dehydrogenase kinases in human livers. J Aichi Med Univ Assoc. 2001, 29: 75-81.
18.
go back to reference Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM: Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J. 1998, 329: 191-196.PubMedCentralCrossRefPubMed Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM: Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J. 1998, 329: 191-196.PubMedCentralCrossRefPubMed
19.
go back to reference Peters JM, Cattley RC, Gonzalez FJl: Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis. 1997, 18: 2029-2033. 10.1093/carcin/18.11.2029.CrossRefPubMed Peters JM, Cattley RC, Gonzalez FJl: Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis. 1997, 18: 2029-2033. 10.1093/carcin/18.11.2029.CrossRefPubMed
20.
go back to reference Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T: Interaction of hepatitis C virus core protein with retinoid X receptor α modulates its transcriptional activity. Hepatology. 2002, 35: 937-946. 10.1053/jhep.2002.32470.CrossRefPubMed Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T: Interaction of hepatitis C virus core protein with retinoid X receptor α modulates its transcriptional activity. Hepatology. 2002, 35: 937-946. 10.1053/jhep.2002.32470.CrossRefPubMed
21.
go back to reference Roy PG, Thompson AM: Cyclin D1 and breast cancer. Breast. 2006, 15: 718-727. 10.1016/j.breast.2006.02.005.CrossRefPubMed Roy PG, Thompson AM: Cyclin D1 and breast cancer. Breast. 2006, 15: 718-727. 10.1016/j.breast.2006.02.005.CrossRefPubMed
22.
go back to reference Polsy D, Cordon-Cardo C: Oncogene in melanoma. Oncogene. 2003, 22: 3087-3091. 10.1038/sj.onc.1206449.CrossRef Polsy D, Cordon-Cardo C: Oncogene in melanoma. Oncogene. 2003, 22: 3087-3091. 10.1038/sj.onc.1206449.CrossRef
23.
go back to reference He Y, Franco OE, Jiang M, Williams K, Love HD, Coleman IM, Nelson PS, Hayward SW: Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer Res. 2007, 67 (17): 8188-8197. 10.1158/0008-5472.CAN-07-0418.CrossRefPubMed He Y, Franco OE, Jiang M, Williams K, Love HD, Coleman IM, Nelson PS, Hayward SW: Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer Res. 2007, 67 (17): 8188-8197. 10.1158/0008-5472.CAN-07-0418.CrossRefPubMed
24.
go back to reference Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, Weinstein IB: Amplication and over expression of cyclin D1 in human hepatocellular carcinoama. Biochem Biophys Res Commun. 1993, 196 (2): 1010-016. 10.1006/bbrc.1993.2350.CrossRefPubMed Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, Weinstein IB: Amplication and over expression of cyclin D1 in human hepatocellular carcinoama. Biochem Biophys Res Commun. 1993, 196 (2): 1010-016. 10.1006/bbrc.1993.2350.CrossRefPubMed
25.
go back to reference Choi MJ, Jung KH, Kim D, Lee H, Zheng HM, Park BH, Hong SW, Kim MH, Hong S, Hong SS: Anti-cancer effects of a novel compound HS-113 on cell growth, apoptosis, and angiogenesis in human hepatocellular carcinoma cells. Cancer Lett. 2011, 306: 190-196. 10.1016/j.canlet.2011.03.005.CrossRefPubMed Choi MJ, Jung KH, Kim D, Lee H, Zheng HM, Park BH, Hong SW, Kim MH, Hong S, Hong SS: Anti-cancer effects of a novel compound HS-113 on cell growth, apoptosis, and angiogenesis in human hepatocellular carcinoma cells. Cancer Lett. 2011, 306: 190-196. 10.1016/j.canlet.2011.03.005.CrossRefPubMed
26.
go back to reference Yokomizo C, Yamaguchi K, Ito Y, Nishimura T, Umemura A, Minami M, Yasui K, Mitsuyoshi H, Fujii H, Tochiki N, Nakajima T, Okanoue T, Yoshikawa T: High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells. Cancer Lett. 2011, 310: 140-147. 10.1016/j.canlet.2011.06.030.CrossRefPubMed Yokomizo C, Yamaguchi K, Ito Y, Nishimura T, Umemura A, Minami M, Yasui K, Mitsuyoshi H, Fujii H, Tochiki N, Nakajima T, Okanoue T, Yoshikawa T: High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells. Cancer Lett. 2011, 310: 140-147. 10.1016/j.canlet.2011.06.030.CrossRefPubMed
27.
go back to reference Chevalier S, Roberts RA: Pertubation of rodent hepatocyte growth control by nongenotoxic hepatocarcinogens: mechanisms and lack of relevance for human health (review). Oncol Rep. 1998, 5: 1319-1327.PubMed Chevalier S, Roberts RA: Pertubation of rodent hepatocyte growth control by nongenotoxic hepatocarcinogens: mechanisms and lack of relevance for human health (review). Oncol Rep. 1998, 5: 1319-1327.PubMed
Metadata
Title
Peroxisome proliferator-activated receptor α (PPARα) mRNA expression in human hepatocellular carcinoma tissue and non-cancerous liver tissue
Authors
Tsuyoshi Kurokawa
Yoshiharu Shimomura
Gustavo Bajotto
Katsuhiro Kotake
Takashi Arikawa
Nobuhiro Ito
Akira Yasuda
Hiroshi Nagata
Toshiaki Nonami
Kazuo Masuko
Publication date
01-12-2011
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2011
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-9-167

Other articles of this Issue 1/2011

World Journal of Surgical Oncology 1/2011 Go to the issue